The millimeters-wide opening of the inner ear has long stymied efforts at drug delivery, but progress is being made, according to Scientific American. Draper Lab is working to create a small intracochlear device designed to treat hearing loss.
Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.
MIT's Robert Langer took home the Queen Elizabeth Prize for his many contributions to drug delivery, including the development of controlled-release polymers, drug-delivering wafers and work on drug-eluting stents.
Not quite a venture firm, research institute or startup, PureTech is a bit of all three. The mission of the early stage research company just got a little bit easier--it bumped up its recent fundraising to $107 million from the $57 million it had raised as of October.
Cerulean Pharma announced last week that the first patient has received its Phase I/IIa cancer candidate, CRLX301, delivered using its RNA-based Dynamic Tumor Targeting Platform.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.
With small but prestigious contributions from the scientific community, SQZ Biotech is looking to launch its CellSqueeze platform to be used in commercial applications.
BOSTON--Master scientist and entrepreneur Robert Langer offered his thoughts on those topics and their relationship to drug delivery to FierceDrugDelivery in his MIT office and later to the field at large at the Partnership Opportunities in Drug Delivery conference in Boston.
A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.
Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.